Soluble MICA in malignant diseases
Soluble MICA in malignant diseases
复制标题
DOI：
10.1002/ijc.21382
复制
发表时间：
2006-03-01
影响因子：
6.4
通讯作者：
Salih, HR
中科院分区：
文献类型：
--
作者：
Holdenrieder, S;Stieber, P;Salih, HR
免疫受体NKG2D激活自然杀伤细胞并共刺激CD8 T细胞。主要组织相容性复合体（MHC）I类相关的MICA分子是NKG2D的配体，在恶性细胞上表达，但不在正常细胞上表达。由于NKG2D在肿瘤的免疫监视中起重要作用，研究表明癌细胞释放MICA构成了一种免疫逃逸机制，会全身性地损害抗肿瘤免疫。在此，我们研究了可溶性MICA（sMICA）作为癌症标志物的潜力。对512个人的血清中sMICA的分析显示，各种恶性肿瘤患者（n = 296，中位数为161 pg/ml）的水平显著（p < 0.0001）高于健康个体（n = 62，中位数<30 pg/ml）。良性疾病患者（n = 154，中位数为84 pg/ml）的sMICA水平处于中间值。在癌症患者中，升高的sMICA水平与癌症分期和转移显著相关（分别为p = 0.015和p = 0.007）。虽然MICA的释放被认为会损害肿瘤免疫，但sMICA水平的测定可能在癌症的诊断和分期中提供有用的补充信息。（c）2005威利 - 利斯公司
The immunoreceptor NKG2D activates natural killer cells and costimulates CD8 T cells. The MHC class I-related MICA molecules are ligands of NKG2D and are expressed on malignant, but not on normal, cells. As NKG2D plays an important role in the immunosurveillance of tumors, studies suggest that release of MICA from cancer cells constitutes an immune escape mechanism that systemically impairs antitumor immunity. Here, we investigated the potential of soluble MICA (sMICA) as a marker in cancer. Analysis of sMICA in sera of 512 individuals revealed significantly (p < 0.0001) higher levels in patients with various malignancies (n = 296, median 161 pg/ml) than in healthy individuals (n = 62, median < 30 pg/ml). Patients with benign diseases (n = 154, median 84 pg/ml) exhibited intermediate sMICA levels. In cancer patients, elevated sMICA levels correlated significantly with cancer stage and metastasis (p = 0.015 and p = 0.007, respectively). While release of MICA is thought to impair tumor immunity, determination of sMICA levels may provide useful additional information in the diagnosis and staging of cancer. (c) 2005 Wiley-Liss, Inc.